Drug Combination for Treatment of Proliferative Diseases

Angiogenesis inhibitory drug combination obtained according to a specific algorithm, preferably a FSC, in which an initial combination of drugs is iteratively adjusted. The drug combination according to the invention may advantageously comprise a RAPTA-C compound. In a more specific case the combination comprises RAPTA-C and eriotinib.


Année
2017
Autres identifiants:
EPO Family ID: 52875103
TTO: 6.1380
Laboratoires:




 Notice créée le 2017-05-02, modifiée le 2019-06-15


Évaluer ce document:

Rate this document:
1
2
3
 
(Pas encore évalué)